SithInvest

AbbVie (ABBV) buying Allergan is under appreciated ( Read full article here ) ABBV is a large biopharmaceutical corporation whose success is primarily driven by the blockbuster drug Humira, which makes up about 60% of the company's revenue. ABBV needs to diversify its revenue stream and pipeline and find a use for the current torrent of cash Humira produces. After combining AGN, Humira will likely be less than 40% of total revenue. ABBV will likely be able to finance this transaction and possibly refinance some existing debt at very low rates, where the lower interest expense will fund research and dividend increases. Read full article here .